Previous 10 | Next 10 |
Like most small cap biotech investors I’m always looking for stocks that sell off following early phase clinical trial results although an efficacy signal is present and investment thesis intact. It is not surprising that these sell-the-news events occur as short term biotech traders ...
Gainers: Equillium (NASDAQ: EQ ) +220% . More news on: Equillium, Inc., electroCore, Inc., WiMi Hologram Cloud Inc., Stocks on the move, , Read more ...
Thinly traded micro cap Gritstone Oncology (NASDAQ: GRTS ) slumps 32% premarket on increased volume on the heels of its presentation of interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen therapeutic vaccine ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Four names in biotechnology are seeing call-outs from Baird for potentially significant upside, and third-quarter catalysts that could give their stocks a boost. More news on: Homology Medicines, Inc., Dicerna Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Healthcare stocks news,...
EMERYVILLE, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the Gritstone management team will host an invest...
EMERYVILLE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executiv...
Gritstone Oncology (NASDAQ: GRTS ): Q1 GAAP EPS of -$0.71 beats by $0.01 . More news on: Gritstone Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
EMERYVILLE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the first quarter ended March 31...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...